1
|
Kim DK, Lee HJ, Lee IH, Lee JJ. Immunomodulatory Effects of Primed Tonsil-Derived Mesenchymal Stem Cells on Atopic Dermatitis via B Cell Regulation. Cells 2023; 13:80. [PMID: 38201284 PMCID: PMC10777933 DOI: 10.3390/cells13010080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2023] [Revised: 12/25/2023] [Accepted: 12/27/2023] [Indexed: 01/12/2024] Open
Abstract
Mesenchymal stem cells (MSCs) ameliorate T-and B cell-mediated immune responses. In particular, tonsil-MSCs (T-MSCs) are attractive candidates for practical and clinical applications because of their ease of acquisition and relatively low immunogenicity compared with other MSC sources. The use of MSCs as a therapeutic tool in atopic dermatitis (AD) has been investigated, but that of T-MSCs remains to be explored. Therefore, we investigated the immunomodulatory effects of primed T-MSCs in AD pathogenesis. In our animal study, primed T-MSCs showed greater immunological suppressive effects than naïve T-MSCs. Additionally, in vitro, the proliferation of B cells was downregulated by the addition of primed T-MSCs compared with naïve T-MSCs. The activation of B cells to differentiate into antibody-secreting cells and produce IgE was also reduced when primed T-MSCs were added. Moreover, under CD40-knockdown conditions, we found that CD40 in primed T-MSCs played a critical role as a regulator of B cell activation and was mediated by the non-canonical NF-κB pathway. Therefore, our findings suggest a promising role for primed T-MSCs in the treatment of AD by regulating B cell-mediated inflammatory responses, which are dependent on CD40 expression on primed T-MSCs mediated through the non-canonical NF-κB pathway.
Collapse
Affiliation(s)
- Dong-Kyu Kim
- Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
- Institute of New Frontier Research, Division of Big Data and Artificial Intelligence, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
| | - Hyun-Joo Lee
- Institute of New Frontier Research, Division of Big Data and Artificial Intelligence, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
| | - Il Hwan Lee
- Department of Otorhinolaryngology-Head and Neck Surgery, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
| | - Jae-Jun Lee
- Institute of New Frontier Research, Division of Big Data and Artificial Intelligence, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
- Department of Anesthesiology and Pain Medicine, College of Medicine, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea
| |
Collapse
|
2
|
Chang QX, Lyu JL, Wu PY, Wen KC, Chang CC, Chiang HM. Coffea arabica Extract Attenuates Atopic Dermatitis-like Skin Lesions by Regulating NLRP3 Inflammasome Expression and Skin Barrier Functions. Int J Mol Sci 2023; 24:12367. [PMID: 37569742 PMCID: PMC10418848 DOI: 10.3390/ijms241512367] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2023] [Revised: 07/27/2023] [Accepted: 07/31/2023] [Indexed: 08/13/2023] Open
Abstract
Atopic dermatitis (AD) is a common skin disease worldwide. The major causes of AD are skin barrier defects, immune dysfunction, and oxidative stress. In this study, we investigated the anti-oxidation and anti-inflammation effects of Coffea arabica extract (CAE) and its regulation of the skin barrier and immune functions in AD. In vitro experiments revealed that CAE decreased the reactive oxygen species levels and inhibited the translocation of nuclear factor-κB (NF-κB), further reducing the secretion of interleukin (IL)-1β and IL-6 induced by interferon-γ (IFN-γ)/tumor necrosis factor-α (TNF-α). Moreover, CAE decreased IFN-γ/TNF-α-induced NLR family pyrin domain-containing 3 (NLRP3), caspase-1, high-mobility group box 1 (HMGB1), and receptor for advanced glycation end products (RAGE) expression levels. It also restored the protein levels of skin barrier function-related markers including filaggrin and claudin-1. In vivo experiments revealed that CAE not only reduced the redness of the backs of mice caused by 2,4-dinitrochlorobenzene (DNCB) but also reduced the levels of pro-inflammatory factors in their skin. CAE also reduced transepidermal water loss (TEWL) and immune cell infiltration in DNCB-treated mice. Overall, CAE exerted anti-oxidation and anti-inflammation effects and ameliorated skin barrier dysfunction, suggesting its potential as an active ingredient for AD treatment.
Collapse
Affiliation(s)
- Qiao-Xin Chang
- Department of Cosmeceutics, China Medical University, Taichung 406, Taiwan; (Q.-X.C.); (J.-L.L.); (K.-C.W.); (C.-C.C.)
| | - Jia-Ling Lyu
- Department of Cosmeceutics, China Medical University, Taichung 406, Taiwan; (Q.-X.C.); (J.-L.L.); (K.-C.W.); (C.-C.C.)
- Ph.D. Program for Biotechnology Industry, China Medical University, Taichung 406, Taiwan
| | - Po-Yuan Wu
- Department of Dermatology, China Medical University Hospital, Taichung 404, Taiwan;
- School of Medicine, China Medical University, Taichung 404, Taiwan
| | - Kuo-Ching Wen
- Department of Cosmeceutics, China Medical University, Taichung 406, Taiwan; (Q.-X.C.); (J.-L.L.); (K.-C.W.); (C.-C.C.)
| | - Chang-Cheng Chang
- Department of Cosmeceutics, China Medical University, Taichung 406, Taiwan; (Q.-X.C.); (J.-L.L.); (K.-C.W.); (C.-C.C.)
- School of Medicine, China Medical University, Taichung 404, Taiwan
| | - Hsiu-Mei Chiang
- Department of Cosmeceutics, China Medical University, Taichung 406, Taiwan; (Q.-X.C.); (J.-L.L.); (K.-C.W.); (C.-C.C.)
- Ph.D. Program for Biotechnology Industry, China Medical University, Taichung 406, Taiwan
| |
Collapse
|
3
|
Najera J, Hao J. Recent advance in mesenchymal stem cells therapy for atopic dermatitis. J Cell Biochem 2023; 124:181-187. [PMID: 36576973 DOI: 10.1002/jcb.30365] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2022] [Revised: 11/07/2022] [Accepted: 12/19/2022] [Indexed: 12/29/2022]
Abstract
Mesenchymal stem cells (MSCs) are multipotent cells found in a variety of tissues in the body, including but not limited to bone marrow, adipose tissue, umbilical cord, and umbilical cord blood. Given their immunomodulatory effect and ability to be readily isolated from several tissues, they have great potential to be used as a therapeutic agent in a variety of immune-mediated disorders. Atopic dermatitis (AD) is a persistent and relapsing immune skin condition that has recently become more common in several species such as humans, canines, equines, and felines. The use of MSCs to treat AD has piqued the great interest of researchers in recent years. In this article, we review the recent understanding of AD pathology and advances in preclinical and clinical studies of MSCs, MSCs-derived conditional media and exosomes as therapeutic tools to treat AD.
Collapse
Affiliation(s)
- Jonathan Najera
- College of Veterinary Medicine, Western University of Health Sciences, Pomona, California, USA.,Department of Biology, College of Science, California State University Polytechnic University, Pomona, California, USA
| | - Jijun Hao
- College of Veterinary Medicine, Western University of Health Sciences, Pomona, California, USA
| |
Collapse
|
4
|
Yang J, Xiao M, Ma K, Li H, Ran M, Yang S, Yang Y, Fu X, Yang S. Therapeutic effects of mesenchymal stem cells and their derivatives in common skin inflammatory diseases: Atopic dermatitis and psoriasis. Front Immunol 2023; 14:1092668. [PMID: 36891306 PMCID: PMC9986293 DOI: 10.3389/fimmu.2023.1092668] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2022] [Accepted: 01/31/2023] [Indexed: 02/22/2023] Open
Abstract
Chronic skin inflammatory diseases including atopic dermatitis (AD) and psoriasis have been considered uncontrolled inflammatory responses, which have usually troubled patients around the world. Moreover, the recent method to treat AD and psoriasis has been based on the inhibition, not regulation, of the abnormal inflammatory response, which can induce a number of side effects and drug resistance in long-term treatment. Mesenchymal stem/stromal cells (MSCs) and their derivatives have been widely used in immune diseases based on their regeneration, differentiation, and immunomodulation with few adverse effects, which makes MSCs a promising treatment for chronic skin inflammatory diseases. As a result, in this review, we aim to systematically discuss the therapeutic effects of various resources of MSCs, the application of preconditioning MSCs and engineering extracellular vesicles (EVs) in AD and psoriasis, and the clinical evaluation of the administration of MSCs and their derivatives, which can provide a comprehensive vision for the application of MSCs and their derivatives in future research and clinical treatment.
Collapse
Affiliation(s)
- Jie Yang
- Department of Dermatology, 4th Medical Centre, PLA General Hospital, Beijing, China.,Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China
| | - Minglu Xiao
- Department of Dermatology, 4th Medical Centre, PLA General Hospital, Beijing, China.,Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China
| | - Kui Ma
- Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China
| | - Hongyu Li
- Department of Dermatology, 4th Medical Centre, PLA General Hospital, Beijing, China.,Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China.,Tianjin Medical University, Tianjin, China
| | - Mingzi Ran
- Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China
| | - Shuxu Yang
- Department of Dermatology, 4th Medical Centre, PLA General Hospital, Beijing, China.,Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China
| | - Yuguang Yang
- Department of Dermatology, 4th Medical Centre, PLA General Hospital, Beijing, China
| | - Xiaobing Fu
- Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China
| | - Siming Yang
- Department of Dermatology, 4th Medical Centre, PLA General Hospital, Beijing, China.,Research Centre for Tissue Repair and Regeneration Affiliated to the Medical Innovation Research Department, PLA General Hospital and PLA Medical College, Beijing, China
| |
Collapse
|
5
|
Singh A. A Comprehensive Review of Therapeutic Approaches Available for the Treatment of Dermatitis. RECENT PATENTS ON NANOTECHNOLOGY 2022; 16:172-197. [PMID: 34365934 DOI: 10.2174/1872210515666210806143015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/04/2021] [Revised: 04/16/2021] [Accepted: 05/24/2021] [Indexed: 06/13/2023]
Abstract
BACKGROUND Dermatitis or eczema is a prevalent skin disorder worldwide and is also very common as a pediatric inflammatory skin disorder. Its succession gets worse with the multiple comorbidities which exhibit mechanisms that are poorly understood. Its management further becomes a challenge due to the limited effective treatment options available. However, the Novel Drug Delivery Systems (NDDS) along with new targeting strategies can easily bypass the issues associated with dermatitis management. If we compare the active constituents against phytoconstituents effective against dermatitis then phytoconstituents can be perceived to be more safe and gentle. OBJECTIVE Administration of NDDS of plant extract or actives displays improved absorption behavior, which helps them to permeate through lipid-rich biological membrane leading to increased bioavailability. The newer efficient discoveries related to eczema can face various exploitations. This can be intervened by the subjection of patent rights, which not only safeguard the novel works of individual(s) but also give them the opportunity to share details of their inventions with people globally. CONCLUSION The present review focuses on the available research about the use of nanoformulations in the topical delivery. It further elaborates the use of different animal models as the basis to characterize the different features of dermatitis. The review also highlights the recent nanoformulations which have the ability to amplify the delivery of active agents through their incorporation in transfersomes, ethosomes, niosomes or phytosomes, etc.
Collapse
Affiliation(s)
- Apoorva Singh
- Department of Pharmaceutics, Amity Institute of Pharmacy, Amity University Uttar Pradesh, Lucknow, India
| |
Collapse
|
6
|
Daltro SRT, Meira CS, Santos IP, Ribeiro dos Santos R, Soares MBP. Mesenchymal Stem Cells and Atopic Dermatitis: A Review. Front Cell Dev Biol 2020; 8:326. [PMID: 32478072 PMCID: PMC7240073 DOI: 10.3389/fcell.2020.00326] [Citation(s) in RCA: 20] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2020] [Accepted: 04/16/2020] [Indexed: 12/16/2022] Open
Abstract
Mesenchymal stem/stromal cells (MSCs) are stromal-derived non-hematopoietic progenitor cells that reside in and can be expanded from various tissues sources of adult and neonatal origin, such as the bone marrow, umbilical cord, umbilical cord blood, adipose tissue, amniotic fluid, placenta, dental pulp and skin. The discovery of the immunosuppressing action of MSCs on T cells has opened new perspectives for their use as a therapeutic agent for immune-mediated disorders, including allergies. Atopic dermatitis (AD), a chronic and relapsing skin disorder that affects up to 20% of children and up to 3% of adults worldwide, is characterized by pruritic eczematous lesions, impaired cutaneous barrier function, Th2 type immune hyperactivation and, frequently, elevation of serum immunoglobulin E levels. Although, in the dermatology field, the application of MSCs as a therapeutic agent was initiated using the concept of cell replacement for skin defects and wound healing, accumulating evidence have shown that MSC-mediated immunomodulation can be applicable to the treatment of inflammatory/allergic skin disorders. Here we reviewed the pre-clinical and clinical studies and possible biological mechanisms of MSCs as a therapeutic tool for the treatment of atopic dermatitis.
Collapse
Affiliation(s)
| | | | | | - Ricardo Ribeiro dos Santos
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Health Institute of Technology, National Industrial Learning Service - Integrated Manufacturing and Technology Campus (SENAI-CIMATEC), Salvador, Brazil
- National Institute of Science and Technology for Regenerative Medicine (INCT-REGENERA), Rio de Janeiro, Brazil
| | - Milena Botelho Pereira Soares
- Gonçalo Moniz Institute, Oswaldo Cruz Foundation (FIOCRUZ), Salvador, Brazil
- Health Institute of Technology, National Industrial Learning Service - Integrated Manufacturing and Technology Campus (SENAI-CIMATEC), Salvador, Brazil
- National Institute of Science and Technology for Regenerative Medicine (INCT-REGENERA), Rio de Janeiro, Brazil
| |
Collapse
|
7
|
Kim WK, Jang YJ, Han DH, Seo B, Park S, Lee CH, Ko G. Administration of Lactobacillus fermentum KBL375 Causes Taxonomic and Functional Changes in Gut Microbiota Leading to Improvement of Atopic Dermatitis. Front Mol Biosci 2019; 6:92. [PMID: 31612141 PMCID: PMC6777006 DOI: 10.3389/fmolb.2019.00092] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2019] [Accepted: 09/11/2019] [Indexed: 12/20/2022] Open
Abstract
Gut microbiota play an important role in immune responses and energy metabolism. In this study, we evaluated whether administration of Lactobacillus fermentum (L. fermentum) KBL375 isolated from healthy Korean feces improves the atopic dermatitis using the house dust mite (Dermatophagoides farinae)-induced atopic dermatitis (AD) mouse model. Administration of L. fermentum KBL375 significantly decreased dermatitis score, ear and dorsal thickness, and serum immunoglobulin E level in AD-induced mice. Significant reductions in mast cells and eosinophils were discovered in skin tissues from L. fermentum KBL375-treated mice. T helper 2 cell-related cytokines interleukin (IL)-4, IL-5, IL-13, and IL-31 significantly decreased, and anti-inflammatory cytokine IL-10 or transforming growth factor-β increased in skin tissues from L. fermentum KBL375-treated mice. In addition to phenotypic changes in skin tissues, L. fermentum KBL375 treatment induced an increase in the CD4+CD25+Foxp3+ cell population in mesenteric lymph nodes. Taxonomic and functional analyses of gut microbiota showed significantly higher cecum bacterial diversities and abundances including genus Bilophila, Dorea, and Dehalobacterium in L. fermentum KBL375-treated mice. Metabolic analysis of the cecum also showed significant changes in the levels of various amino acids including methionine, phenylalanine, serine, and tyrosine, as well as short chain fatty acids such as acetate, butyrate, and propionate in AD-induced mice due to L. fermentum KBL375 treatment. These altered metabolites in AD-induced mice returned to the levels similar to those in control mice when treated with L. fermentum KBL375. Therefore, L. fermentum KBL375 could be useful for AD treatment by modulating the immune system and inducing various metabolites.
Collapse
Affiliation(s)
- Woon-Ki Kim
- Graduate School of Public Health, Seoul National University, Seoul, South Korea
- N-Bio, Seoul National University, Seoul, South Korea
| | - You Jin Jang
- Graduate School of Public Health, Seoul National University, Seoul, South Korea
| | - Dae Hee Han
- Graduate School of Public Health, Seoul National University, Seoul, South Korea
| | - Boram Seo
- Graduate School of Public Health, Seoul National University, Seoul, South Korea
| | - SungJun Park
- Graduate School of Public Health, Seoul National University, Seoul, South Korea
- N-Bio, Seoul National University, Seoul, South Korea
- KoBioLabs, Inc., Seoul, South Korea
| | - Chang Hyung Lee
- Department of Agricultural Biotechnology, Seoul National University, Seoul, South Korea
| | - GwangPyo Ko
- Graduate School of Public Health, Seoul National University, Seoul, South Korea
- N-Bio, Seoul National University, Seoul, South Korea
- KoBioLabs, Inc., Seoul, South Korea
- Center for Human and Environmental Microbiome, Seoul National University, Seoul, South Korea
- Institute of Health and Environment, Seoul National University, Seoul, South Korea
| |
Collapse
|
8
|
Kim IS, Lee SH, Kim JA, Yu DY, Hong YH, Kim JY, Lim JM, Lee SS, Yun CH, Choi IS, Cho KK. Effect of oral administration of β-glucans derived from Aureobasidium pullulans SM-2001 in model mice and rat with atopic dermatitis-like phenotypes. Food Sci Biotechnol 2018; 27:1185-1192. [PMID: 30263849 DOI: 10.1007/s10068-018-0322-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/17/2017] [Revised: 01/15/2018] [Accepted: 01/18/2018] [Indexed: 12/20/2022] Open
Abstract
In this study, we investigated the anti-atopic dermatitis (AD) activity of β-glucans derived from Aureobasidium pullulans SM-2001 (βGdAP). βGdAP was orally administered to AD animal models such as vasodilation, allergic pruritus and contact dermatitis. Administration of βGdAP attenuated the amount of Evans blue solution on vasodilation rat. Scratching behaviors, secretion of histamine and ear thickness were significantly (p < 0.05) attenuated in the βGdAP-treated mouse groups. Interestingly, transcriptional expression of T-bet, a transcription factor for Th1 reactions, was increased, but that of GATA-3, a transcription factor for Th2 reactions, was attenuated in the βGdAP-treated groups (p < 0.05). In addition, we found that reduced transcriptional expression of forkhead box P3 and galectin-9, regulators of regulatory T cells, was recovered in the βGdAP-treated groups (p < 0.05). Taken together, these data indicate that administration of βGdAP could effectively attenuate AD-like phenotypes via regulation of Th1/Th2 transcriptional activity and Treg activation.
Collapse
Affiliation(s)
- In Sung Kim
- 1Department of Animal Resources Technology, Gyeongnam National University of Science and Technology, Jinju, 52725 Korea
| | - Seung Ho Lee
- 2Department of Nano-Bioengineering, Incheon National University, Incheon, 22012 Korea
| | - Jeong A Kim
- 1Department of Animal Resources Technology, Gyeongnam National University of Science and Technology, Jinju, 52725 Korea
| | - Da Yoon Yu
- 1Department of Animal Resources Technology, Gyeongnam National University of Science and Technology, Jinju, 52725 Korea
| | - Yeon Hee Hong
- 1Department of Animal Resources Technology, Gyeongnam National University of Science and Technology, Jinju, 52725 Korea
| | - Jae Young Kim
- 3Swine Science and Technology Center, Gyeongnam National University of Science and Technology, Jinju, 52725 Korea
| | | | - Sang Suk Lee
- 5Department of Animal Science and Technology, Sunchon National University, Suncheon, 57922 Korea
| | - Cheol-Heui Yun
- 6Department of Agricultural Biotechnology, Seoul National University, Seoul, 08826 Korea
| | - In Soon Choi
- 7Departmnet of Life Science, Silla University, Busan, 46958 Korea
| | - Kwang Keun Cho
- 1Department of Animal Resources Technology, Gyeongnam National University of Science and Technology, Jinju, 52725 Korea
| |
Collapse
|
9
|
Lim H, Yo S, Lee M, Seo C, Shin H, Jeong S. Potential inhibitory effects of the traditional herbal prescription Hyangso-san against skin inflammation via inhibition of chemokine production and inactivation of STAT1 in HaCaT keratinocytes. Mol Med Rep 2017; 17:2515-2522. [DOI: 10.3892/mmr.2017.8172] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/15/2016] [Accepted: 04/20/2017] [Indexed: 11/06/2022] Open
Affiliation(s)
- Hye‑Sun Lim
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Yuseong, Daejeon 34054, Republic of Korea
| | - Sae‑Rom Yo
- K-herb Research Center, Korea Institute of Oriental Medicine, Yuseong, Daejeon 34054, Republic of Korea
| | - Mee‑Young Lee
- K-herb Research Center, Korea Institute of Oriental Medicine, Yuseong, Daejeon 34054, Republic of Korea
| | - Chang‑Seob Seo
- K-herb Research Center, Korea Institute of Oriental Medicine, Yuseong, Daejeon 34054, Republic of Korea
| | - Hyeun‑Kyoo Shin
- K-herb Research Center, Korea Institute of Oriental Medicine, Yuseong, Daejeon 34054, Republic of Korea
| | - Soo‑Jin Jeong
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Yuseong, Daejeon 34054, Republic of Korea
| |
Collapse
|
10
|
Harris VR, Cooper AJ. Atopic dermatitis: the new frontier. Med J Aust 2017; 207:351-356. [DOI: 10.5694/mja17.00463] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/15/2017] [Accepted: 08/18/2017] [Indexed: 01/04/2023]
|
11
|
Lee SH, Yoon JM, Kim YH, Jeong DG, Park S, Kang DJ. Therapeutic effect of tyndallized Lactobacillus rhamnosus IDCC 3201 on atopic dermatitis mediated by down-regulation of immunoglobulin E in NC/Nga mice. Microbiol Immunol 2017; 60:468-76. [PMID: 27240551 DOI: 10.1111/1348-0421.12390] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/26/2016] [Revised: 05/20/2016] [Accepted: 05/24/2016] [Indexed: 01/09/2023]
Abstract
The therapeutic effect of oral administration of Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) on atopic dermatitis (AD)-like skin lesions in NC/Nga mice were investigated. After induction of dermatitis in NC/Nga mice with house-dust mite extract, each group was fed RHT3201 with 1 × 10(8) , 1 × 10(9) , or 1 × 10(10) cells orally once a day for 8 weeks. Dermatitis scores and frequency of scratching were improved by oral feeding with RHT3201. In contrast to the control group, RHT3201-fed mice showed significantly down-regulated mast cell numbers and serum immunoglobulin E (IgE) concentrations had significantly less IL4 in their axillary lymph node cells. The therapeutic effect of RHT3201 was found to be dose-dependent. These findings indicate that RHT3201 has potential for treating AD.
Collapse
Affiliation(s)
- Seung-Hun Lee
- Research Laboratories, Ildong Pharmaceutical, 20, Samsung 1-ro 1-gil, Hwaseong 18449.,Department of Biotechnology and Bioengineering, Konkuk University, 120, Neungdong-ro, Gwangjin-gu, Seoul 05029, Korea
| | - Jong-Min Yoon
- Research Laboratories, Ildong Pharmaceutical, 20, Samsung 1-ro 1-gil, Hwaseong 18449
| | - Young-Hoo Kim
- Research Laboratories, Ildong Pharmaceutical, 20, Samsung 1-ro 1-gil, Hwaseong 18449
| | - Dong-Gu Jeong
- Research Laboratories, Ildong Pharmaceutical, 20, Samsung 1-ro 1-gil, Hwaseong 18449
| | - Soobong Park
- Research Laboratories, Ildong Pharmaceutical, 20, Samsung 1-ro 1-gil, Hwaseong 18449
| | - Dae-Jung Kang
- Research Laboratories, Ildong Pharmaceutical, 20, Samsung 1-ro 1-gil, Hwaseong 18449
| |
Collapse
|
12
|
Selected immunological parameters in clinical evaluation of patients with atopic dermatitis. Postepy Dermatol Alergol 2016; 33:211-8. [PMID: 27512357 PMCID: PMC4969417 DOI: 10.5114/ada.2016.60614] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2014] [Accepted: 05/18/2015] [Indexed: 02/04/2023] Open
Abstract
Introduction It has been suggested that soluble immune receptors (SIRs) such as sCD25 and sCD30 may serve as potential biomarkers in evaluation of atopic dermatitis (AD). Previous studies clearly indicated that serum levels of interleukin (IL)-13 and total IgE (tIgE) might be potentially useful in the evaluation of patents with AD. Aim To evaluate whether serum levels of sCD25 and sCD30 are suitable biomarkers of AD. Moreover, we have decided to estimate the usefulness of tIgE and IL-13 serum level determination in the evaluated population. Material and methods A group of 102 AD patients was investigated. Serum concentrations of sCD30, sCD25, IL-13 and tIgE were measured. The clinical phenotype of AD was classified as extrinsic (ADe) or intrinsic (ADi) based on the presence of IgE. Statistical analysis was performed to estimate correlations between obtained results and clinical features of the population such as AD phenotype, age, disease extent and severity. Results Extrinsic AD was diagnosed in 71% of patients, while ADi phenotype was observed in 29% of the investigated population. A negative correlation between serum levels of sCD25 and sCD30 and disease severity as well patients’ age was established. Serum levels of IL-13 did not reach the cut-off point set by the manufacturer. A positive correlation between serum levels of total IgE and disease severity and patients’ age was observed. Conclusions This paper shows that serum levels of sCD25 and sCD30 as well as tIgE are age dependent. Determination of serum levels of sCD25, sCD30 and IL-13 is not useful in everyday practice.
Collapse
|
13
|
Jeong SJ, Lim HS, Seo CS, Kim JH, Jin SE, Yoo SR, Shin HK. Traditional herbal formula Jakyakgamcho-tang (Paeonia lactiflora and Glycyrrhiza uralensis) impairs inflammatory chemokine production by inhibiting activation of STAT1 and NF-κB in HaCaT cells. PHYTOMEDICINE : INTERNATIONAL JOURNAL OF PHYTOTHERAPY AND PHYTOPHARMACOLOGY 2015; 22:326-32. [PMID: 25765840 DOI: 10.1016/j.phymed.2014.12.002] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/18/2014] [Revised: 10/28/2014] [Accepted: 12/14/2014] [Indexed: 05/08/2023]
Abstract
A traditional herbal formula Jakyakgamcho-tang (JYGCT; Paeonia lactiflora and Glycyrrhiza uralensis) has been used for treatment of backache, muscle pain, acute abdominal pain, neuralgia, bronchial asthma, and painful peripheral neuropathy in Oriental medicine. We report on our experiments using the HaCaT human keratinocyte cell line showing that a traditional herbal formula JYGCT has inhibitory effects on inflammatory responses in skin. Stimulation with tumour necrosis factor-alpha (TNF-α) and interferon-gamma (IFN-γ) caused a significant increase in the production of the following chemokines: thymus- and activation-regulated chemokine (TARC)/CCL17; macrophage-derived chemokine (MDC)/CCL22; regulated on activation, normal T-cell expressed and secreted (RANTES)/CCL5; and interleukin-8 (IL-8) in HaCaT cells. By contrast, treatment with JYGCT extract significantly reduced the production of TARC, MDC, RANTES, and IL-8, but caused no cytotoxicity, compared with TNF-α and IFN-γ-treated control cells. Consistently, JYGCT extract downregulated the mRNA expression of TARC, MDC, RANTES, and IL-8 induced by TNF-α and IFN-γ in a dose-dependent manner. In addition, TNF-α and IFN-γ markedly increased the phosphorylation of signal transducer and activator of transcription 1 (STAT1) and the nuclear translocation of nuclear factor kappa B (NF-κB) in HaCaT cells. By contrast, TNF-α and IFN-γ-induced activation of STAT1 and NF-κB activation was inhibited by JYGCT treatment in a dose-dependent manner. Our data indicate that JYGCT attenuates TNF-α and IFN-γ-mediated chemokine production by targeting the STAT1 and NF-κB signalling in keratinocytes. Our findings suggest that JYGCT has potential as a therapeutic drug candidate for the treatment of inflammatory skin diseases.
Collapse
Affiliation(s)
- Soo-Jin Jeong
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea
| | - Hye-Sun Lim
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea; Division of Allergy and Chronic Respiratory Diseases, Center for Biomedical Sciences, Korea National Institute of Health, Chungcheongbuk-do 361-951, Republic of Korea
| | - Chang-Seob Seo
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea
| | - Jung-Hoon Kim
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea; Division of Pharmacology, Pusan National University School of Korean Medicine, Yangsan City, Gyeongnam 626-870, Republic of Korea
| | - Seong-Eun Jin
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea
| | - Sae-Rom Yoo
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea
| | - Hyeun-Kyoo Shin
- Herbal Medicine Research Division, Korea Institute of Oriental Medicine, Daejeon 305-811, Republic of Korea.
| |
Collapse
|
14
|
Daeschlein G, Scholz S, Lutze S, Eming R, Arnold A, Haase H, Hertl M, Jünger M. Repetitive Immunoadsorption Cycles for Treatment of Severe Atopic Dermatitis. Ther Apher Dial 2014; 19:279-87. [DOI: 10.1111/1744-9987.12267] [Citation(s) in RCA: 16] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2014] [Revised: 07/21/2014] [Indexed: 11/27/2022]
Affiliation(s)
- Georg Daeschlein
- Department of Dermatology; University of Greifswald; Greifswald Germany
| | - Sebastian Scholz
- Department of Dermatology; University of Greifswald; Greifswald Germany
| | - Stine Lutze
- Department of Dermatology; University of Greifswald; Greifswald Germany
| | - Ruediger Eming
- Department of Dermatology and Allergology; University of Marburg; Marburg Germany
| | - Andreas Arnold
- Department of Dermatology; University of Greifswald; Greifswald Germany
| | - Hermann Haase
- Department of Dermatology; University of Greifswald; Greifswald Germany
| | - Michael Hertl
- Department of Dermatology and Allergology; University of Marburg; Marburg Germany
| | - Michael Jünger
- Department of Dermatology; University of Greifswald; Greifswald Germany
| |
Collapse
|
15
|
Hong SH, Kim SR, Choi HS, Ku JM, Seo HS, Shin YC, Ko SG. Effects of Hyeonggaeyeongyo-tang in ovalbumin-induced allergic rhinitis model. Mediators Inflamm 2014; 2014:418705. [PMID: 25221386 PMCID: PMC4158145 DOI: 10.1155/2014/418705] [Citation(s) in RCA: 9] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2014] [Accepted: 05/25/2014] [Indexed: 01/23/2023] Open
Abstract
Allergic rhinitis (AR) is an allergic inflammation of the nasal airways. The prevalence of AR is increasing worldwide. We investigated whether Hyeonggaeyeongyo-tang (HYT) is effective to suppress the progression of AR induced by ovalbumin (OVA). Male BALB/c mice were used for this study. Allergic rhinitis was induced by OVA. Treatment with HYT was assessed to study the effect of HYT on allergic rhinitis in mice. Histological analysis, immunohistochemistry, multiplex cytokine assay, blood analysis, and cell viability assay were performed to verify inhibitory effect of HYT on allergic rhinitis. HYT did not show any toxicity maintaining body weight. Food intake was steady without variation in mice. HYT reduced infiltration of inflammatory cells and mast cells into nasal cavity. HYT reduced the levels of cytokines and leukocytes in the blood. HYT decreased the splenocyte cell viability. Antihistamines and steroids are the most common medications used to treat allergic rhinitis. However, long-term use of drug generates resistance or side effects requiring the development of new drug. Our present study clearly demonstrates that HYT suppresses the progression of allergic rhinitis induced by OVA. This suggests that HYT might be a useful drug for the treatment of allergic rhinitis.
Collapse
Affiliation(s)
- Se Hyang Hong
- Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Soon Re Kim
- Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Han-Seok Choi
- Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Jin Mo Ku
- Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Hye Sook Seo
- Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Yong Cheol Shin
- Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| | - Seong-Gyu Ko
- Laboratory of Clinical Biology and Pharmacogenomics, Department of Preventive Medicine, College of Oriental Medicine, Kyung Hee University, Seoul 130-701, Republic of Korea
| |
Collapse
|
16
|
Schönefuss A, Wendt W, Schattling B, Schulten R, Hoffmann K, Stuecker M, Tigges C, Lübbert H, Stichel C. Upregulation of cathepsin S in psoriatic keratinocytes. Exp Dermatol 2011; 19:e80-8. [PMID: 19849712 DOI: 10.1111/j.1600-0625.2009.00990.x] [Citation(s) in RCA: 50] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
Cathepsin S (CATS) is a cysteine protease, well known for its role in MHC class II-mediated antigen presentation and extracellular matrix degradation. Disturbance of the expression or metabolism of this protease is a concomitant feature of several diseases. Given this importance we studied the localization and regulation of CATS expression in normal and pathological human/mouse skin. In normal human skin CATS-immunostaining is mainly present in the dermis and is localized in macrophages, Langerhans, T- and endothelial cells, but absent in keratinocytes. In all analyzed pathological skin biopsies, i.e. atopic dermatitis, actinic keratosis and psoriasis, CATS staining is strongly increased in the dermis. But only in psoriasis, CATS-immunostaining is also detectable in keratinocytes. We show that cocultivation with T-cells as well as treatment with cytokines can trigger expression and secretion of CATS, which is involved in MHC II processing in keratinocytes. Our data provide first evidence that CATS expression (i) is selectively induced in psoriatic keratinocytes, (ii) is triggered by T-cells and (iii) might be involved in keratinocytic MHC class II expression, the processing of the MHC class II-associated invariant chain and remodeling of the extracellular matrix. This paper expands our knowledge on the important role of keratinocytes in dermatological disease.
Collapse
|
17
|
|
18
|
Sawada J, Morita H, Tanaka A, Salminen S, He F, Matsuda H. Ingestion of heat-treated Lactobacillus rhamnosus GG prevents development of atopic dermatitis in NC/Nga mice. Clin Exp Allergy 2007; 37:296-303. [PMID: 17250703 DOI: 10.1111/j.1365-2222.2006.02645.x] [Citation(s) in RCA: 83] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Abstract
BACKGROUND Continuous oral administration of live Lactobacillus rhamnosus GG (L. GG) to pregnant subjects with atopic dermatitis and their children, suppressed the frequency of atopic dermatitis. The details of mechanisms and immune systems involved in this suppressive effect, however, remain speculative. OBJECTIVE We sought to clarify suppressive mechanisms of L. GG on atopic dermatitis by using NC/Nga mice, a model of human atopic dermatitis. METHODS Maternal mice and infant mice were fed with food containing or not containing heat-treated L. GG during pregnancy and breastfeeding, and after weaning. RESULTS Control NC/Nga mice raised under an air-uncontrolled condition spontaneously manifested typical skin lesions very similar to those in patients with atopic dermatitis. On the other hand, administration of food containing heat-treated L. GG inhibited the onset and development of atopic skin lesions, accompanied by smaller numbers of mast cells and eosinophils in the affected skin sites. Mice fed with L. GG showed a significant increase in plasma IL-10 levels compared with control mice, while there was no significant difference in the proportion of splenic CD4(+)CD25(+) regulatory T cells between mice fed with L. GG and control mice. The IL-10 mRNA expression was enhanced in both Peyer's patches and mesenteric lymph nodes in mice fed with L. GG. CONCLUSION These findings suggest that some components of heat-treated L. GG may have an ability to delay the onset and suppress the development of atopic dermatitis, probably through a strong induction of IL-10 in intestinal lymphoid organs and systemic levels.
Collapse
Affiliation(s)
- J Sawada
- Laboratory of Veterinary Molecular Pathology and Therapeutics, Division of Animal Life Science, Graduate School, Institute of Symbiotic Science and Technology, Tokyo University of Agriculture and Technology, Tokyo, Japan
| | | | | | | | | | | |
Collapse
|
19
|
Abramovits W, Perlmutter A. Steroids versus other immune modulators in the management of allergic dermatoses. Curr Opin Allergy Clin Immunol 2007; 6:345-54. [PMID: 16954788 DOI: 10.1097/01.all.0000244795.41357.6e] [Citation(s) in RCA: 14] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
Abstract
PURPOSE OF REVIEW The classic role of topical and systemic corticosteroids for allergic dermatoses is discussed, with special attention to the impact on the current clinical treatment paradigm by newer systemic and topical therapies. These products are reviewed and recommendations presented on how to effectively assimilate them into clinical practice. RECENT FINDINGS Current knowledge about the etiopathogenesis of atopic dermatitis has resulted in drug development focused on agents with less toxicity than current topical and systemic corticosteroids. Some agents with ceramide/cholesterol/acid combinations demonstrate efficacy in restoring the dysfunctional skin barrier of atopic patients. Concerns resulting from the recent Federal Drug Administration announcement regarding a theoretical risk of cancer associated with topical calcineurin inhibitors are also addressed. Novel therapeutic entities are presented. SUMMARY Patients seeking relief from atopic dermatitis have historically had few really effective and safe therapeutic options. Topical calcineurin inhibitors represent an exciting new therapy for atopic dermatitis without the side-effect profile associated with topical corticosteroids. Nonsteroidal formulations incorporating glycyrrhetinic acid/telmesteine/Vitis vinifera extract and palmitoylethanolamide as 'active' ingredients recently entered the market, stressing antipruritic, antiinflammatory, and skin barrier repair. This confabulates against previously designed topical therapy paradigms. These new products may be used as monotherapy or alternatives to steroid agents.
Collapse
|
20
|
Abstract
Since the discovery of cytokines as key mediators in inflammation, targeting the cytokine network has represented a promising therapeutic approach. Psoriasis and atopic dermatitis, as T cell-mediated diseases with a strong cytokine component and a high unmet medical need, have moved into the focus of experimental therapies. Whereas pro-inflammatory cytokines such as tumor necrosis factor (TNF)-alpha are overexpressed in both diseases, a type 1 cytokine pattern predominates in psoriasis and a type 2 cytokine pattern is of pathophysiological importance at least in the initial stages of atopic dermatitis. Strategies for intervention into the cytokine network have included antagonism of pro-inflammatory cytokines (e.g. TNFalpha, interleukin [IL]-1, IL-8, IL-12, IL-18, IL-23) with neutralizing antibodies and soluble receptors, application of recombinant cytokines (e.g. IL-4, IL-10, IL-11, interferon [IFN]-gamma) to shift the cytokine balance, and administration of small molecules to modulate cytokine expression or signaling. Results from the clinic have led to novel therapeutic options as well as a better understanding of the pathophysiology of inflammatory skin diseases. This review highlights the various therapeutic strategies, results from the clinic (that are in some cases preliminary), and insights that can be drawn from the more advanced clinical studies and the use of approved cytokine-directed therapies.
Collapse
Affiliation(s)
- Robert P Numerof
- Research Business Area Dermatology USA, Berlex Biosciences, Richmond, California 94804-0099, USA.
| | | |
Collapse
|
21
|
Park CW, Lee BH, Han HJ, Lee CH, Ahn HK. Tacrolimus decreases the expression of eotaxin, CCR3, RANTES and interleukin-5 in atopic dermatitis. Br J Dermatol 2005; 152:1173-81. [PMID: 15948978 DOI: 10.1111/j.1365-2133.2005.06474.x] [Citation(s) in RCA: 40] [Impact Index Per Article: 2.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Abstract
BACKGROUND There is a lack of studies on the effect of tacrolimus on eosinophils and related molecules including eotaxin, CCR3, RANTES and interleukin (IL)-5. OBJECTIVES To investigate the effects of tacrolimus on in vivo eosinophil counts and on the related molecules eotaxin, CCR3, RANTES and IL-5 in patients with atopic dermatitis (AD). METHODS Lesional skin specimens and sera were obtained from 15 patients with AD and from 15 normal controls. For 8 weeks, the patients with AD applied 0.03% tacrolimus ointment to all affected areas twice daily. Blood sampling and skin biopsies were then repeated. We evaluated serum eotaxin and IL-5 levels, and tissue eotaxin, CCR3, RANTES and IL-5 levels. Additionally, tissue levels of eotaxin and CCR3 mRNA were measured. RESULTS After treatment with topical tacrolimus twice daily for 8 weeks, significant decreases were found in serum IL-5 levels, immunoreactive cell counts of eotaxin, IL-5, CCR3 and RANTES in AD skin, and tissue eosinophil counts. However, the change in the serum eosinophil count was not statistically significant, and mRNA levels of eotaxin and CCR3 were not decreased significantly after treatment. CONCLUSIONS Topical tacrolimus reduces the number of eosinophils in tissue and suppresses the expression of eotaxin, CCR3, RANTES and IL-5 related to proliferation, recruitment, activation and survival of eosinophils.
Collapse
MESH Headings
- Adolescent
- Adult
- Biomarkers/analysis
- Biomarkers/blood
- Case-Control Studies
- Chemokine CCL11
- Chemokine CCL5/analysis
- Chemokines, CC/analysis
- Chemokines, CC/blood
- Chemokines, CC/genetics
- Child
- Child, Preschool
- Dermatitis, Atopic/drug therapy
- Dermatitis, Atopic/immunology
- Eosinophilia/drug therapy
- Eosinophilia/immunology
- Female
- Humans
- Immunohistochemistry/methods
- Immunosuppressive Agents/administration & dosage
- Immunosuppressive Agents/therapeutic use
- Interleukin-5/analysis
- Interleukin-5/blood
- Korea
- Leukocyte Count
- Male
- Ointments
- RNA, Messenger/analysis
- Receptors, CCR3
- Receptors, Chemokine/analysis
- Receptors, Chemokine/genetics
- Reverse Transcriptase Polymerase Chain Reaction
- Skin/drug effects
- Skin/immunology
- Tacrolimus/administration & dosage
- Tacrolimus/therapeutic use
Collapse
Affiliation(s)
- C W Park
- Department of Dermatology, Kang-Nam Sacred Heart Hospital, College of Medicine, Hallym University, Youngdeungpo-Gu, Seoul 150-950, Korea.
| | | | | | | | | |
Collapse
|
22
|
Wolff K, Fleming C, Hanifin J, Papp K, Reitamo S, Rustin M, Shear N, Silny W, Korman N, Marks I, Cherill R, Emady-Azar S, Paul C. Efficacy and tolerability of three different doses of oral pimecrolimus in the treatment of moderate to severe atopic dermatitis: a randomized controlled trial. Br J Dermatol 2005; 152:1296-303. [PMID: 15948996 DOI: 10.1111/j.1365-2133.2005.06674.x] [Citation(s) in RCA: 28] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Abstract
BACKGROUND Adult atopic dermatitis (AD) can seriously affect quality of life of patients and their families, and patients' disease is frequently not satisfactorily controlled with topical therapy. There is a need for alternatives to topical treatment in patients with moderate to severe AD. OBJECTIVES To investigate the efficacy and safety of oral pimecrolimus, and to determine the response to three different doses in the treatment of AD. METHODS In a double-blind, placebo-controlled, parallel-group, dose-finding study, patients with moderate to severe AD were randomized to receive either placebo, or oral pimecrolimus 10, 20 or 30 mg twice daily. The study consisted of a pretreatment phase, a 12-week double-blind treatment phase, and a 12-week post-treatment phase. RESULTS In total, 103 patients were randomized. A clear, dose-dependent therapeutic effect of pimecrolimus treatment was observed, with a statistically significant onset of efficacy at week 2 and the greatest reduction from baseline of the Eczema Area and Severity Index of 66.6% at week 7 in the 30 mg twice daily dose group. Oral pimecrolimus was well tolerated and there were no signs of nephrotoxicity or the induction of hypertension. CONCLUSIONS These data demonstrate the clinically relevant efficacy and short-term safety of oral pimecrolimus in adults with moderate to severe AD. Longer-term studies in larger cohorts are now required.
Collapse
Affiliation(s)
- K Wolff
- Department of Dermatology, Medical University of Vienna, Austria
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
23
|
Abstract
Tacrolimus ointment (Protopic) is a topically applied macrolide lactone immunomodulator effective in the treatment of atopic dermatitis. Its mechanism of action primarily involves calcineurin inhibition, which interrupts cytokine gene expression and leads to the downregulation of T-cell activity. Tacrolimus ointment (0.03% and 0.1% for adults and 0.03% for children) is an effective treatment for atopic dermatitis of the trunk and limbs, as well as sensitive skin areas such as the face. Its efficacy is similar to or greater than that of hydrocortisone acetate 1%, hydrocortisone butyrate 0.1% and betamethsone valerate 0.12% ointments and pimecrolimus 1% cream. Systemic absorption of tacrolimus from the ointment is minimal, and adverse events, which are mostly associated with the application site and include skin burning and pruritus, tend to resolve early in treatment. Unlike topical corticosteroids, tacrolimus ointment is not associated with skin atrophy, and it is a well tolerated treatment for adults or children with atopic dermatitis, particularly when long-term treatment is indicated or the face or skin-fold regions are involved.
Collapse
Affiliation(s)
- Dene Simpson
- Adis International Limited, Auckland, New Zealand.
| | | |
Collapse
|